175 related articles for article (PubMed ID: 35619182)
1. Novel dual-targeting c-Myc inhibitor D347-2761 represses myeloma growth via blocking c-Myc/Max heterodimerization and disturbing its stability.
Yao R; Zhang M; Zhou J; Liu L; Zhang Y; Gao J; Xu K
Cell Commun Signal; 2022 May; 20(1):73. PubMed ID: 35619182
[TBL] [Abstract][Full Text] [Related]
2. Identification of a novel c-Myc inhibitor with antitumor effects on multiple myeloma cells.
Yao R; Sun X; Xie Y; Sun X; Yao Y; Li H; Li Z; Gao J; Xu K
Biosci Rep; 2018 Oct; 38(5):. PubMed ID: 30068698
[TBL] [Abstract][Full Text] [Related]
3. Identification of a Novel c-Myc Inhibitor 7594-0037 by Structure-Based Virtual Screening and Investigation of Its Anti-Cancer Effect on Multiple Myeloma.
Yao R; Xie Y; Sun X; Zhang M; Zhou J; Liu L; Gao J; Xu K
Drug Des Devel Ther; 2020; 14():3983-3993. PubMed ID: 33061303
[TBL] [Abstract][Full Text] [Related]
4. RNA Polymerase I Inhibition with CX-5461 as a Novel Therapeutic Strategy to Target MYC in Multiple Myeloma.
Lee HC; Wang H; Baladandayuthapani V; Lin H; He J; Jones RJ; Kuiatse I; Gu D; Wang Z; Ma W; Lim J; O'Brien S; Keats J; Yang J; Davis RE; Orlowski RZ
Br J Haematol; 2017 Apr; 177(1):80-94. PubMed ID: 28369725
[TBL] [Abstract][Full Text] [Related]
5. ATF4 destabilizes RET through nonclassical GRP78 inhibition to enhance chemosensitivity to bortezomib in human osteosarcoma.
Luo J; Xia Y; Yin Y; Luo J; Liu M; Zhang H; Zhang C; Zhao Y; Yang L; Kong L
Theranostics; 2019; 9(21):6334-6353. PubMed ID: 31534554
[No Abstract] [Full Text] [Related]
6. Depletion of circ_0007841 inhibits multiple myeloma development and BTZ resistance via miR-129-5p/JAG1 axis.
Wang Y; Lin Q; Song C; Ma R; Li X
Cell Cycle; 2020 Dec; 19(23):3289-3302. PubMed ID: 33131409
[TBL] [Abstract][Full Text] [Related]
7. Targeting an MDM2/MYC Axis to Overcome Drug Resistance in Multiple Myeloma.
Faruq O; Zhao D; Shrestha M; Vecchione A; Zacksenhaus E; Chang H
Cancers (Basel); 2022 Mar; 14(6):. PubMed ID: 35326742
[TBL] [Abstract][Full Text] [Related]
8. A novel 2-iminobenzimidazole compound, XYA1353, displays in vitro and in vivo anti-myeloma activity via targeting NF-κB signaling.
Gao J; Zhou J; Zhang M; Zhang Y; Zeng Y; Li S; Xu K; Yao R
Mol Cell Biochem; 2024 Apr; 479(4):843-857. PubMed ID: 37204666
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of hsa_circ_0003489 shifts balance from autophagy to apoptosis and sensitizes multiple myeloma cells to bortezomib via miR-874-3p/HDAC1 axis.
Tian FQ; Chen ZR; Zhu W; Tang MQ; Li JH; Zhang XC; Jiang J; Cheng XH
J Gene Med; 2021 Sep; 23(9):e3329. PubMed ID: 33625798
[TBL] [Abstract][Full Text] [Related]
10. A novel inhibitor L755507 efficiently blocks c-Myc-MAX heterodimerization and induces apoptosis in cancer cells.
Singh A; Kumar A; Kumar P; Nayak N; Bhardwaj T; Giri R; Garg N
J Biol Chem; 2021 Jul; 297(1):100903. PubMed ID: 34157284
[TBL] [Abstract][Full Text] [Related]
11. Addiction to c-MYC in multiple myeloma.
Holien T; Våtsveen TK; Hella H; Waage A; Sundan A
Blood; 2012 Sep; 120(12):2450-3. PubMed ID: 22806891
[TBL] [Abstract][Full Text] [Related]
12. Computer-aided drug discovery of Myc-Max inhibitors as potential therapeutics for prostate cancer.
Carabet LA; Lallous N; Leblanc E; Ban F; Morin H; Lawn S; Ghaidi F; Lee J; Mills IG; Gleave ME; Rennie PS; Cherkasov A
Eur J Med Chem; 2018 Dec; 160():108-119. PubMed ID: 30326371
[TBL] [Abstract][Full Text] [Related]
13. CircRNA ITCH increases bortezomib sensitivity through regulating the miR-615-3p/PRKCD axis in multiple myeloma.
Liu J; Du F; Chen C; Li D; Chen Y; Xiao X; Hou X
Life Sci; 2020 Dec; 262():118506. PubMed ID: 33031827
[TBL] [Abstract][Full Text] [Related]
14. Myc interacts with Max and Miz1 to repress C/EBPdelta promoter activity and gene expression.
Si J; Yu X; Zhang Y; DeWille JW
Mol Cancer; 2010 Apr; 9():92. PubMed ID: 20426839
[TBL] [Abstract][Full Text] [Related]
15. Protein targeting chimeric molecules specific for bromodomain and extra-terminal motif family proteins are active against pre-clinical models of multiple myeloma.
Zhang X; Lee HC; Shirazi F; Baladandayuthapani V; Lin H; Kuiatse I; Wang H; Jones RJ; Berkova Z; Singh RK; Lu J; Qian Y; Raina K; Coleman KG; Crews CM; Li B; Wang H; Hailemichael Y; Thomas SK; Wang Z; Davis RE; Orlowski RZ
Leukemia; 2018 Oct; 32(10):2224-2239. PubMed ID: 29581547
[TBL] [Abstract][Full Text] [Related]
16. Blockade of deubiquitinase USP7 overcomes bortezomib resistance by suppressing NF-κB signaling pathway in multiple myeloma.
Yao Y; Zhang Y; Shi M; Sun Y; Chen C; Niu M; Zhang Q; Zeng L; Yao R; Li H; Yang J; Li Z; Xu K
J Leukoc Biol; 2018 Dec; 104(6):1105-1115. PubMed ID: 30024656
[TBL] [Abstract][Full Text] [Related]
17. A novel M phase blocker, DCZ3301 enhances the sensitivity of bortezomib in resistant multiple myeloma through DNA damage and mitotic catastrophe.
Hu L; Li B; Chen G; Song D; Xu Z; Gao L; Xi M; Zhou J; Li L; Zhang H; Feng Q; Wang Y; Lu K; Lu Y; Bu W; Wang H; Wu X; Zhu W; Shi J
J Exp Clin Cancer Res; 2020 Jun; 39(1):105. PubMed ID: 32517809
[TBL] [Abstract][Full Text] [Related]
18. Gamabufotalin triggers c-Myc degradation via induction of WWP2 in multiple myeloma cells.
Yu Z; Li T; Wang C; Deng S; Zhang B; Huo X; Zhang B; Wang X; Zhong Y; Ma X
Oncotarget; 2016 Mar; 7(13):15725-37. PubMed ID: 26894970
[TBL] [Abstract][Full Text] [Related]
19. ZHX2 mediates proteasome inhibitor resistance via regulating nuclear translocation of NF-κB in multiple myeloma.
Jiang J; Sun Y; Xu J; Xu T; Xu Z; Liu P
Cancer Med; 2020 Oct; 9(19):7244-7252. PubMed ID: 32780537
[TBL] [Abstract][Full Text] [Related]
20. IL6 Promotes a STAT3-PRL3 Feedforward Loop via SHP2 Repression in Multiple Myeloma.
Chong PSY; Zhou J; Lim JSL; Hee YT; Chooi JY; Chung TH; Tan ZT; Zeng Q; Waller DD; Sebag M; Chng WJ
Cancer Res; 2019 Sep; 79(18):4679-4688. PubMed ID: 31337650
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
